Ebola vaccine from GSK to begin U.S. clinical trials within weeks-sources

NEW YORK, Aug 27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people familiar with the plans.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.